Suppr超能文献

与羊膜带序列相关的肢体缺陷的风险因素和流行率:一项基于人群的病例对照研究。

Risk Factors and Prevalence of Limb Deficiencies Associated With Amniotic Band Sequence: A Population-based Case-control Study.

机构信息

Departments of Paediatric Surgery and Orthopaedics.

Department of Paediatric Surgery, Kuopio University Hospital, Kuopio.

出版信息

J Pediatr Orthop. 2021 Jan;41(1):e94-e97. doi: 10.1097/BPO.0000000000001686.

Abstract

BACKGROUND

Limb deficiencies associated with amniotic bands comprise a wide range of congenital anomalies. The association of maternal medication and the risk of amniotic band sequence (ABS) has not yet been addressed.

METHODS

This nationwide population-based case-control study used national registers on congenital anomalies, births and induced abortions, cross-linked with information on maternal prescription medicine use obtained from the registers on Reimbursed Drug Purchases and Medical Special Reimbursements. All cases with congenital limb deficiency associated with amniotic bands born between 1996 and 2008 were included in the study. Five controls without limb deficiency matched for residency and time of conception were randomly selected from the Medical Birth Register.

RESULTS

In total, 106 children with limb deficiency associated with ABS were identified and compared with 530 matched controls. Young maternal age (less than 25 y) increased the risk of limb deficiencies [odds ratio=1.72; 95% confidence interval (CI): 1.06, 2.80]. Primiparity was also associated with increased risk [adjusted odds ratio (aOR)=2.42; 95% CI: 1.52, 3.88]. After adjusting for maternal age, pregestational diabetes, and parity, maternal use of beta-blockers (adjusted OR=24.2; 95% CI: 2.57, 228) and progestogens (adjusted OR=3.79; 95% CI: 1.38, 10.4) during the first trimester of pregnancy significantly increased the risk of limb deficiencies associated with amniotic bands.

CONCLUSIONS

Primiparity significantly increased the risk of limb defects associated with amniotic bands. Also, a novel association on increased risk of ABS with maternal use of progestogens or beta-blockers during the first trimester of pregnancy was observed.

LEVEL OF EVIDENCE

Level III.

摘要

背景

与羊膜带相关的肢体缺陷包括广泛的先天性异常。母亲用药与羊膜带序列(ABS)风险之间的关联尚未得到解决。

方法

本全国性基于人群的病例对照研究使用了先天性异常、出生和人工流产国家登记处,以及从报销药品购买和医疗特别报销登记处获得的母亲处方药使用信息进行交叉链接。所有 1996 年至 2008 年间出生的与羊膜带相关的先天性肢体缺陷病例均纳入研究。从医疗出生登记处随机选择 5 名与居住地和受孕时间相匹配、无肢体缺陷的对照。

结果

共确定了 106 例与 ABS 相关的肢体缺陷患儿,并与 530 名匹配对照进行比较。年轻母亲年龄(小于 25 岁)增加了肢体缺陷的风险[比值比(OR)=1.72;95%置信区间(CI):1.06,2.80]。初产妇也与风险增加相关[调整后的 OR(aOR)=2.42;95% CI:1.52,3.88]。在校正了母亲年龄、孕前糖尿病和产次后,母亲在妊娠早期使用β受体阻滞剂(调整 OR=24.2;95% CI:2.57,228)和孕激素(调整 OR=3.79;95% CI:1.38,10.4)显著增加了与羊膜带相关的肢体缺陷的风险。

结论

初产妇显著增加了与羊膜带相关的肢体缺陷的风险。此外,还观察到妊娠早期母亲使用孕激素或β受体阻滞剂与 ABS 风险增加之间存在新的关联。

证据水平

三级。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验